Fosså Alexander, Berner Aasmund, Fosså Sophie D, Hernes Eivor, Gaudernack Gustav, Smeland Erlend B
Department of Immunology, The Norwegian Radium Hospital, Montebello, Oslo, Norway.
Prostate. 2004 Jun 1;59(4):440-7. doi: 10.1002/pros.20025.
Due to restricted expression in normal tissues cancer/testis (C/T) antigens represent candidate molecules for immunotherapy of cancer. NY-ESO-1 is a well-studied C/T antigen with unknown expression and immunogenicity in prostate cancer (PC) patients.
NY-ESO-1 expression was determined by immunohistochemistry and humoral immune responses against NY-ESO-1 assessed by enzyme-linked immuno-sorbent assay (ELISA) and Western blotting. Protein expression and serological responses were correlated with clinical findings and survival.
NY-ESO-1 expression was found in biopsies from 2 of 66 localized PC and 7/48 hormone refractory prostate cancer (HRPC) patients, respectively. Anti-NY-ESO-1 antibodies were detected in sera from 1 of 112 localized PC and 18 of 95 HRPC patients. Two of four HRPC patients with NY-ESO-1 positive biopsies had mounted a serological response. Positive anti-NY-ESO-1 titers were correlated with poor survival in HRPC patients.
NY-ESO-1 is expressed in a subset of HRPC patients and, together with other C/T antigens, may serve as a target antigen for development of immunotherapy of PC. Spontaneous serological responses against NY-ESO-1 may be associated with poor survival.
由于在正常组织中表达受限，癌胚/睾丸（C/T）抗原成为癌症免疫治疗的候选分子。NY-ESO-1是一种研究充分的C/T抗原，其在前列腺癌（PC）患者中的表达及免疫原性尚不清楚。
通过免疫组织化学测定NY-ESO-1的表达，并采用酶联免疫吸附测定（ELISA）和蛋白质印迹法评估针对NY-ESO-1的体液免疫反应。将蛋白质表达和血清学反应与临床发现及生存率相关联。
在66例局限性PC患者中的2例以及48例激素难治性前列腺癌（HRPC）患者中的7例的活检组织中发现了NY-ESO-1表达。在112例局限性PC患者中的1例以及95例HRPC患者中的18例的血清中检测到了抗NY-ESO-1抗体。4例NY-ESO-1活检阳性的HRPC患者中有2例产生了血清学反应。抗NY-ESO-1滴度阳性与HRPC患者的不良生存相关。
NY-ESO-1在一部分HRPC患者中表达，并且与其他C/T抗原一起，可能作为PC免疫治疗开发的靶抗原。针对NY-ESO-1的自发血清学反应可能与不良生存相关。
